Pasar al contenido principal

DESCUBRIR LOS FUNDAMENTOS GENETICOS DE ENFERMEDADES RARAS Y COMUNES CON UN MODELADO PROBABILISTICO PROFUNDO DE LOS DATOS DE SECUENCIA

PID2022-140793NA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO CENTRE DE REGULACIO GENOMICA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Proteome-wide model for human disease genetics

  • Orenbuch, Rose
  • Shearer, Courtney A.
  • Kollasch, Aaron W.
  • Spinner, Aviv D.
  • Hopf, Thomas
  • Niekerk, Lood van
  • Franceschi, Dinko
  • Dias, Mafalda
  • Frazer, Jonathan
  • Marks, Debora S.
Missense variants remain a challenge in genetic interpretation owing to their subtle and context-dependent effects. Although current prediction models perform well in known disease genes, their scores are not calibrated across the proteome, limiting generalizability. To address this knowledge gap, we developed popEVE, a deep generative model combining evolutionary and human population data to estimate variant deleteriousness on a proteome-wide scale. popEVE achieves state-of-the-art performance without overestimating the burden of deleterious variants and identifies variants in 442 genes in a severe developmental disorder cohort, including 123 novel candidates. These genes are functionally similar to known disease genes, and their variants often localize to critical regions. Remarkably, popEVE can prioritize likely causal variants using only child exomes, enabling diagnosis even without parental sequencing. This work provides a generalizable framework for rare disease variant interpretation, especially in singleton cases, and demonstrates the utility of calibrated, evolution-informed scoring models for clinical genomics., We thank all members of the Marks Lab, Dias and Frazer Lab and Sander Lab for valuable discussions. We also thank J. Nicoludis and Invitae for their assistance with training some of the EVE models. R.O., A.W.K., C.A.S., M.D., J.F. and D.S.M. are supported by a Chan Zuckerberg Initiative Award (Neurodegeneration Challenge Network, CZI2018-191853). H.S. and D.S.M. are supported by a National Institutes of Health Transformational Research Award (TR01 1R01CA260415). C.A.S. is supported by the National Science Foundation Graduate Research Fellowship under grant no. DGE-2146755. M.D. and J.F. are supported by the Spanish Ministry of Science and Innovation (PID2022-140793NA-I00) funded by MCIN/AEI/10.13039/501100011033/FEDER, UE) and acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033) and the Generalitat de Catalunya through the CERCA programme.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Guidelines for releasing a variant effect predictor

  • Livesey, Benjamin J.
  • Badonyi, Mihaly
  • Dias, Mafalda
  • Frazer, Jonathan
  • Kumar, Sushant
  • Lindorff-Larsen, Kresten
  • McCandlish, David M.
  • Orenbuch, Rose
  • Shearer, Courtney A.
  • Muffley, Lara
  • Foreman, Julia
  • Glazer, Andrew M.
  • Lehner, Ben, 1978-
  • Marks, Debora S.
  • Roth, Frederick P.
  • Rubin, Alan F.
  • Starita, Lea M.
  • Marsh, Joseph A.
Computational methods for assessing the likely impacts of mutations, known as variant effect predictors (VEPs), are widely used in the assessment and interpretation of human genetic variation, as well as in other applications like protein engineering. Many different VEPs have been released, and there is tremendous variability in their underlying algorithms, outputs, and the ways in which the methodologies and predictions are shared. This leads to considerable difficulties for users trying to navigate the selection and application of VEPs. Here, to address these issues, we provide guidelines and recommendations for the release of novel VEPs., MD and J Frazer are supported by the Spanish Ministry of Science and Innovation (PID2022-140793NA-I00). KLL received funding from the Novo Nordisk Foundation (NNF18OC0033950). DMM received funding from the National Institutes of Health (NIH) (R35GM133613). RO and DSM are supported by the Chan Zuckerberg Initiative Neurodegeneration Challenge Network (CZI2018-191853). LM, LMS, and FPR received funding from the NIH (RM1HG010461), and FPR also received funding from NIH grant UM1HG011989. J Foreman received funding from the Wellcome Trust (WT223718/Z/21/Z). AMG received funding from the NIH (R35GM150465). BL received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 883742). DSM received funding from the NIH (1R01CA260415). AFR received funding from the NIH (UM1HG011969, RM1HG010461, R01HG013025) and grant funding from the Australian Government. JAM is supported by the ERC (grant agreement No. 101001169) and by the Medical Research Council (MRC) Human Genetics Unit core grant (MC_UU_00035/9).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Guidelines for releasing a variant effect predictor

  • Livesey, Benjamin J.
  • Badonyi, Mihaly
  • Dias, Mafalda
  • Frazer, Jonathan
  • Kumar, Sushant
  • Lindorff-Larsen, Kresten
  • McCandlish, David M.
  • Orenbuch, Rose
  • Shearer, Courtney A.
  • Muffley, Lara
  • Foreman, Julia
  • Glazer, Andrew M.
  • Lehner, Ben, 1978-
  • Marks, Debora S.
  • Roth, Frederick P.
  • Rubin, Alan F.
  • Starita, Lea M.
  • Marsh, Joseph A.
Computational methods for assessing the likely impacts of mutations, known as variant effect predictors (VEPs), are widely used in the assessment and interpretation of human genetic variation, as well as in other applications like protein engineering. Many different VEPs have been released, and there is tremendous variability in their underlying algorithms, outputs, and the ways in which the methodologies and predictions are shared. This leads to considerable difficulties for users trying to navigate the selection and application of VEPs. Here, to address these issues, we provide guidelines and recommendations for the release of novel VEPs., MD and J Frazer are supported by the Spanish Ministry of Science and Innovation (PID2022-140793NA-I00). KLL received funding from the Novo Nordisk Foundation (NNF18OC0033950). DMM received funding from the National Institutes of Health (NIH) (R35GM133613). RO and DSM are supported by the Chan Zuckerberg Initiative Neurodegeneration Challenge Network (CZI2018-191853). LM, LMS, and FPR received funding from the NIH (RM1HG010461), and FPR also received funding from NIH grant UM1HG011989. J Foreman received funding from the Wellcome Trust (WT223718/Z/21/Z). AMG received funding from the NIH (R35GM150465). BL received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 883742). DSM received funding from the NIH (1R01CA260415). AFR received funding from the NIH (UM1HG011969, RM1HG010461, R01HG013025) and grant funding from the Australian Government. JAM is supported by the ERC (grant agreement No. 101001169) and by the Medical Research Council (MRC) Human Genetics Unit core grant (MC_UU_00035/9).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Proteome-wide model for human disease genetics

  • Orenbuch, Rose
  • Shearer, Courtney A.
  • Kollasch, Aaron W.
  • Spinner, Aviv D.
  • Hopf, Thomas
  • Niekerk, Lood van
  • Franceschi, Dinko
  • Dias, Mafalda
  • Frazer, Jonathan
  • Marks, Debora S.
Missense variants remain a challenge in genetic interpretation owing to their subtle and context-dependent effects. Although current prediction models perform well in known disease genes, their scores are not calibrated across the proteome, limiting generalizability. To address this knowledge gap, we developed popEVE, a deep generative model combining evolutionary and human population data to estimate variant deleteriousness on a proteome-wide scale. popEVE achieves state-of-the-art performance without overestimating the burden of deleterious variants and identifies variants in 442 genes in a severe developmental disorder cohort, including 123 novel candidates. These genes are functionally similar to known disease genes, and their variants often localize to critical regions. Remarkably, popEVE can prioritize likely causal variants using only child exomes, enabling diagnosis even without parental sequencing. This work provides a generalizable framework for rare disease variant interpretation, especially in singleton cases, and demonstrates the utility of calibrated, evolution-informed scoring models for clinical genomics., We thank all members of the Marks Lab, Dias and Frazer Lab and Sander Lab for valuable discussions. We also thank J. Nicoludis and Invitae for their assistance with training some of the EVE models. R.O., A.W.K., C.A.S., M.D., J.F. and D.S.M. are supported by a Chan Zuckerberg Initiative Award (Neurodegeneration Challenge Network, CZI2018-191853). H.S. and D.S.M. are supported by a National Institutes of Health Transformational Research Award (TR01 1R01CA260415). C.A.S. is supported by the National Science Foundation Graduate Research Fellowship under grant no. DGE-2146755. M.D. and J.F. are supported by the Spanish Ministry of Science and Innovation (PID2022-140793NA-I00) funded by MCIN/AEI/10.13039/501100011033/FEDER, UE) and acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033) and the Generalitat de Catalunya through the CERCA programme.